Academic Journal
Intra-arterial peptide-receptor radionuclide therapy for neuro-endocrine tumour liver metastases:an in-patient randomised controlled trial (LUTIA)
| العنوان: | Intra-arterial peptide-receptor radionuclide therapy for neuro-endocrine tumour liver metastases:an in-patient randomised controlled trial (LUTIA) |
|---|---|
| المؤلفون: | Ebbers, S. C., Barentsz, M. W., de Vries-Huizing, D. M.V., Versleijen, M. W.J., Klompenhouwer, E. G., Tesselaar, M. E.T., Stokkel, M. P.M., Brabander, T., Hofland, J., Moelker, A., van Leeuwaarde, R. S., Smits, M. L.J., Braat, A. J.A.T., Lam, M. G.E.H. |
| المصدر: | Ebbers , S C , Barentsz , M W , de Vries-Huizing , D M V , Versleijen , M W J , Klompenhouwer , E G , Tesselaar , M E T , Stokkel , M P M , Brabander , T , Hofland , J , Moelker , A , van Leeuwaarde , R S , Smits , M L J , Braat , A J A T & Lam , M G E H 2024 , ' Intra-arterial peptide-receptor radionuclide therapy for neuro-endocrine tumour liver metastases : an in-patient randomised controlled trial (LUTIA) ' , European .... |
| سنة النشر: | 2024 |
| الوصف: | Purpose: Peptide receptor radionuclide therapy (PRRT) using [ 177 Lu]Lu-DOTATATE has been shown to effectively prolong progression free survival in grade 1–2 gastroenteropancreatic neuroendocrine tumours (GEP-NET), but is less efficacious in patients with extensive liver metastases. The aim was to investigate whether tumour uptake in liver metastases can be enhanced by intra-arterial administration of [ 177 Lu]Lu-DOTATATE into the hepatic artery, in order to improve tumour response without increasing toxicity. Methods: Twenty-seven patients with grade 1–2 GEP-NET, and bi-lobar liver metastases were randomized to receive intra-arterial PRRT in the left or right liver lobe for four consecutive cycles. The contralateral liver lobe and extrahepatic disease were treated via a “second-pass” effect and the contralateral lobe was used as the control lobe. Up to three metastases (> 3 cm) per liver lobe were identified as target lesions at baseline on contrast-enhanced CT. The primary endpoint was the tumour-to-non-tumour (T/N) uptake ratio on the 24 h post-treatment [ 177 Lu]Lu-SPECT/CT after the first cycle. This was calculated for each target lesion in both lobes using the mean uptake. T/N ratios in both lobes were compared using paired-samples t-test. Findings: After the first cycle, a non-significant difference in T/N uptake ratio was observed: T/N IA = 17·4 vs. T/N control = 16·2 (p = 0·299). The mean increase in T/N was 17% (1·17; 95% CI [1·00; 1·37]). Of all patients, 67% (18/27) showed any increase in T/N ratio after the first cycle. Conclusion: Intra-arterial [ 177 Lu]Lu-DOTATATE is safe, but does not lead to a clinically significant increase in tumour uptake. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| DOI: | 10.1007/s00259-023-06467-y |
| الاتاحة: | https://pure.eur.nl/en/publications/9d9ee73c-4211-40b9-8c0d-a8db3762a893 https://doi.org/10.1007/s00259-023-06467-y https://pure.eur.nl/ws/files/116813285/Intra-arterial_peptide-receptor_radionuclide_therapy_for_neuro-endocrine_tumour_liver_metastases.pdf http://www.scopus.com/inward/record.url?scp=85175080576&partnerID=8YFLogxK |
| Rights: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.51C897CC |
| قاعدة البيانات: | BASE |
| DOI: | 10.1007/s00259-023-06467-y |
|---|